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Abstract:
The first model we are evaluating is human influenza virus in mice. Influenza virus is a
negative sense RNA virus, which the CDC estimates causes between 9.2 million and 35.6
million illnesses each year in the United States. [IJ In the current influenza season, H3N2 viruses
have been the predominant subclade of influenza A virus in circulation. [2l Development of a
mouse model for influenza H3N2 virus infection has been difficult. In these studies, we
endeavored to mouse-adapt influenza A/Hong Kong/4801/2014 H3N2 virus by serial passaging
in AG129 mice. This virus strain was chosen as it overlaps in serotype with the current influenza
H3N2 virus in circulation. [2l Initial passaging was unsuccessful, with no detectable increase in
virus titer. However, when we used Mannan, an innate immune suppressant, as an aid in
adapting the virus to mice, we observed an increase in virus titers in the lung between passage 1
to passage 3.
The second model we are evaluating is mouse Norovirus as a model for Human
Norovirus infections. Human Norovirus is a positive sense RNA virus responsible for
approximately 685 million cases every year across the world . [3l Therefore identification of
antiviral agents for treatment of human norovirus is a priority. We screened potential antiviral
compounds in vitro utilizing a mouse macrophage cell line. rupintrivir, favipiravir , carbodine,
and anicomycin were all observed to have antiviral effects in vitro. In vivo screening of
carbodine will be completed in the mouse model as there is no human norovirus model in vivo.
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1 Introduction:
1.1 Influenza H3N2
Influenza viruses are negative sense RNA viruses from the family Orthomyxoviridae. Seven
genres exist within Orthomyxoviridae, three of which cause infection in humans; influenza type
A, B, and C. Of these three genres, influenza type A and Bare the most prevalent in human
disease. Both viruses have segmented genomes consisting of eight separate segments, whereas
influenza Chas seven separate segments. [4 l Worldwide annual epidemics of influenza virus
cause on average 3 to 5 million severe cases of illness, with an estimated 290,000 - 650,000
respiratory deaths.

[SJ In

addition to the loss of human life influenza virus also represents an

economic burden. In the United States alone influenza virus infection is estimated to cause
annual net economic loss of $4 7 .2 - $ 149.5 billion dollars. (61
In our current influenza season, type A influenza has the been the predominant form of
influenza virus in circulation. [2 l The type A influenza viruses are subdivided based on which
combination of two glycoproteins, hemagglutinin and neuraminidase, they possess.
Neuraminidase is found in 11 different subtypes, numbered NI - NI 1, all of which catalyze the
cleavage of sialic acid, aiding in viral release. [7l Hemagglutinin is found in 18 different subtypes,
numbered HI - H18, all of which are involved in initial binding of the virus to sialic acids. [7l Of
these different subtypes, influenza A subtypes HINI and H3N2 make up the vast majority of
influenza A infections within humans. [2J In this current influenza season, from October 2017 to
April 151\ 2018 there have been 36,858 specimens of influenza A and 50,664 positive samples
of influenza tested by public health laboratories across the united states. Of the 36,858 samples
of influenza A, H3N2 has was the causative agent 84.3% of them. Furthermore, of the 50,664

samples of influenza A and B tested this season, influenza H3N2 was the causati
ve agent in
61.2% of them. r2J
Despite the prevalence of influenza H3N2, development of a mouse model for
the
influenza H3N2 viruses currently in circulation has proven difficult. Given this,
there is demand
for a mouse model of influenza H3N2 for the evaluation of potential therapeutics
against current
H3N2 strains. The CDC has demonstrated that 96.9% of the 509 current influen
za H3N2 viruses
tested were inhibited by ferret antisera generated against A/Michigan/15 /2014
(3C.2a) and a cellpropagated A/Hong Kong/4801/2014-like virus. r2J This suggests that either strain
is likely a
suitable target for the development of a mouse model.

1.2 Human and Morine Norovirus
Human Norovirus and murine norovirus, both lie within a genus of the family
Caliciviridae, and are positive sense, single stranded RNA viruses. Human norovir
us is
responsible for approximately 685 million infections every year across the world
and is the
leading cause of acute gastroenteritis. [3J Lethality from norovirus is normally
restricted to
children, and it is estimated that the virus kills 50,000 children yearly, predom
inately in
developing countries. [3J Additionally it is estimated that human norovirus infectio
n causes a
global economic loss between $44.4 - $83.4 billion dollars.

[SJ

Given the cost to human health and the economic loss resultant from human norovir
us
infection, the discovery of therapeutics for treatment of the virus is a priority.
Despite this,
therapeutic development has historically been slowed by a lack of cell culture
s capable of
supporting human norovirus replication. Instead of in vitro replication to supply
stocks of human
norovirus, these stocks have been harvested from the stools of hospital volunte
ers. [9J In addition
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to difficulties in vitro, there has been no successful development of a reliable, lethal small animal
model for therapeutic evaluation. [9l
Given the difficulties with working with human norovirus, a reasonable alternative which
has been previously proposed is the evaluation of potential therapeutics in a lethal murine
norovirus AG-129 mouse model. Murine and human noroviruses are genetically similar both
containing ~7 .5 kb genome. Human norovirus has three open reading frames (ORFs) and murine
norovirus possesses 4. The first three ORFs encode for equal number of proteins with analogous
functions between the two viruses . [IOJ ORF4, unique to murine norovirus, is encoded within an
alternative reading frame of within ORF2. It encodes virulence factor 1, a mitochondrial
localized novel innate immune regulator , which represents the major genomic difference
between the two viruses.

[I
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While differences exist, the amount of similarities combined with

the ability of murine norovirus to lethally replicate within the RAW 264.7 cell line as well as
AG-129 mice, in a manner reversible by effective antiviral compounds make murine norovirus a
convenient possible alternative model. [121

2 Materials and Methods:
2.1 Animals
This work was done in the Association for Assessment and Accreditation of Laboratory
Animal Care International-accredited, biosafety level 2 laboratory at Utah State University. Male
and female AG129 mice were used and were bred in-house in sterilized cages and maintained in
a 12/12 light cycle. Animals were euthanized by cervical dislocation by a trained technician. An
immune compromised AG-129 strain of mice was chosen as previous attempts to adapt H3N2 in
immune competent strains, such as the BALB /c strain of mice, had proven unsuccessful.

3

2.2 Initial Virus Stock Influenza H3N2
The viral strain utilized was Influenza A Hong Kong/4801/2014 (H3N2) virus. Prior to
passaging in mice, this virus was passaged twice in a Madin-Darby Canine Kidney (MDCK) cell
line to generate sufficient stock for inoculation of mice.

2.3 Initial 5 Passages of Influenza H3N2
Mice ages 5 to 8 weeks old were inoculated intranasally (i.n.) with 90 ul of a 1: 1 solution
of virus stock and a mannan MEM solution. Prior to inoculation, mice were sedated with
Ketamine/Xylazine mixture. Virus harvested from the prior passage was utilized as the stock for
infection of the next passage. Inoculation of passage one utilized the initial virus stock, grown in
MDCK cells. On day one and day two the mice were given an intranasal rinse of sterile saline at
a volume of 90 ul. Three days post inoculation, mice were euthanized by cervical dislocation for
necropsy and harvest of the lungs. Lungs were homogenized in 1 ml of MEM with 50 µg/ml of
gentamycin, for inhibition of bacterial growth in media. Homogenate was divided into two equal
aliquots. One for storage, the other aliquot was pooled with those from other mice in the passage .
This pooled homogenate was utilized to infect the subsequent passage. Passage one was
inoculated with a 50% cell culture infectious dose per ml (CCID50) of 1047 . Passage two was
inoculated with a CCIDS0 of 103 ·97 . Passage three was inoculated with a CCID50 of 105 .36 .
Passage four was inoculated with a CCIDS0 of 105·91 . Passage five was inoculated with a
CCIDS0 of 10553 . All CCID50 values have been adjusted for the ½ reduction from dilution by
mannan MEM solution.

4

2.4 Evaluation of Disease Markers in MP4
Mice ages S to 8 weeks old were inoculated i.n. with a 90 ul, 1: 1 solution of MP4
(CCIDS0 of 105 ·53 , already adjusted for dilution with mannan) and a mannan MEM solution.
Prior to inoculation, mice were sedated with Ketamine/Xylazine mixture. Mice were sedated
with the same Ketamine/Xylazine mixture on day one and two for administration of an intranasal
rinse of sterile saline. Mortality was checked, and mice were weighed daily until euthanasia by
cervical dislocation on day 20.

2.5 Influenza H3N2 Passage with no Mannan and Rinses
Mice ages S to 8 weeks old were divided into three groups, labelled group 1, 2 and 3. All
mice were sedated before viral inoculation. Group 1 was inoculated intranasally with MP3 (at a
CCIDS0 of 1062 ) and group 2 was inoculated intranasally with MPS (at a CCIDS0 of 1060 ).
Group 3 was inoculated with a MPS (at a CCIDS0 of 105·8, already adjusted for dilution with
mannan). Both group 1 and two were not given mannan. All three groups were not given
intranasal rinses on day one or two. Mice were euthanized, and the lungs removed during
necropsy on the third day post infection. In subsequent passaging, all procedures remained the
same, except mice were inoculated with a homogenate from their group's previous passage.

2.6 Intranasal Rinses
Initial attempts at passaging of the influenza H3N2 virus in AG-129 mice were
unsuccessful. In response to this, intranasal rinses were given on day 1 and 2 as they are known
to increase viral titer, and the likelihood of mortality.

[l
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l This effect is possibly mediated by

rinsing the virus deeper into the lungs, exposing it to new cell populations.

s

2.7 Mannan
Mannan is a polysaccharide preparation from Saccharomyce s cerevisiae. It has been
shown previously to increase the ability of influenza A to survive by inhibiting a host defense
collectins , namely mannan-binding lectin, by competing for binding sites with the virus. l 14l
Mannan-binding lectin is a pathogen recognition receptor which can inhibit infection by
complement activation (through the leptin pathway) , opsonization, and direct viral neutralization.
[ISJ

The optimal range for inhibition of collectins for amplification of influenza virus growth has

been demonstrated previously in other strains of influenza virus to be .5 mg/mouse , therefore this
is the dose we utilized. l 161

2.8 Cells and Media Influenza H3N2
Madin-Darby canine kidney Atlanta (MDCK-ATL) cells, were obtained from the
International Reagent Resource (IRR) which is managed under contract by the American Type
Culture Collection (Manassas, VA) and maintained at 37 °C and 5 % CO2 in antibiotic-free cell
culture medium (minimum essential medium with Earle ' s balanced salts and L-glutamine ,
MEM/EBSS) supplemented with 5 % fetal bovine serum (both from HyClone , Fisher Scientific,
Logan, UT). The test medium consisted of MEM/EBSS supplemented with trypsin (10 U/ml) ,
EDTA (1 µg/ml) and gentamicin (50 µg/ml).

2.9 Cells and Media Murine Norovirus
RAW 264.7 murine macrophage cell line were obtained from the American Type Culture
Collection (Manassas , VA) and maintained at 37 °C and 5 % CO2 in antibiotic-free cell culture
medium (minimum essential medium with Earle's balanced salts and L-glutamine , MEM /EBSS)
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supplemented with 10 % fetal bovine serum (both from HyClone, Fisher Scienti
fic, Logan, UT).
The test medium consisted ofMEM/EBSS supplemented with 2% fetal bovine
serum and
gentamicin (50 µg/ml).

2.10 Quantification of Influenza H3N2

The estimated number of virions of influenza H3N2 in all mouse studies was
quantified
by dilution to extinction down 8 wells of a 96 well plate. This plate was seeded
with 4 x 104
MDCK-ALT cells the day prior. Results were read visually at three days post
infection. Visual
reads of cell death were confirmed four days post infection by the neutral red
uptake method.
Plates were treated for 2 hat 37 °C with neutral red (0.011 %) to quantify CPE.
Excess dye was
rinsed from cells with phosphate-buffered saline. The absorbed dye was eluted
by addition of 0.1
ml of 50 % Sorensen ' s citrate buffer/ 50 % ethanol to each well. Optical
density (OD)
measurements were taken using a computerized microplate reader (SPECTRAm
ax ® Plus384,
Molecular Devices Corporation , Sunnyvale, CA) with absorbance measurements
at 560 nm. The
CCID50 was determined using the Reed-Muench method .

2.11 Murine Norovirus

The viral strain used was Murine Norovirus (MNV-1.CWl). Prior to passaging
in mice,
this virus was passaged once in a RAW 264. 7 cell line to generate sufficient stock
for inoculation
of mice.
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2.12 Antiviral Compounds Against Murine Norovirus
The compounds tested were; rupintrivir, carbodine , favipiravir , anisomycin , pirodavir,
guanidine, cyanovirin, azacytadine, 1-Beta-D-arabinofuranisyl and nitazoxanide. azacytadine
was obtained from AcaChem Scientific (San Antonio, TX 78278. U.S.A.) . 1-Beta-Darabinofuranisyl was obtained from the EMD Millipore Corporation (Temecula , CA 92590 ,
U.S.A.). Rupintrivir, carbodine , favipiravir, anisomycin, pirodavir, guanidine, cyanovirin, and
nitazoxanide were provided by the Institute for Antiviral Research (IAR) chemical compound
depository (Utah State University , UT 84321 , U.S.A.). All compounds were dissolved in cell
culture media (minimum essential medium with Earle's balanced salts and L-glutamine,
MEM/EBSS) with gentamicin (50 µg/ml). Concentrations of 320, 32, 3.2, .32, .032, .0032,
.00032, .000032 µg/ml were utilized for nitazoxanide, rupintrivir , carbodine , guanidine,
favipiravir , azacytadine, 1-Beta-D-arabinofuranisyl. Concentrations of 100, 10, 1.0, .1, .01, .001,
.0001, .00001 µg/ml were utilized for anisomycin, cyanovirin and pirodavir.

2.13 In Vitro Antiviral Studies Against Murine Norovirus
The antiviral activity of each drug or drug combination was determined in RAW 264 .7
cells. Effective antiviral concentrations (EC50 values) were computed based on the inhibition of
virus-induced cytopathic effects (CPE) coupled with a neutral red dye uptake method. Ninetysix-well plates were seeded with approximately 8 * 104 RAW 264 .7 cells /well. Following
overnight incubation, cells were infected with approximately 50 times the 50 % cell culture
infectious dose (CCID50) of virus. Microtiter plates were visually examined 4 days post
infection (dpi) and then treated for 2 hat 37 °C with neutral red (0.011 %) to quantify CPE.
Excess dye was rinsed from cells with phosphate-buffered saline. The absorbed dye was eluted

8

by addition of 0.1 ml of 50 % Sorensen's citrate buffer/50 % ethanol to each well. Optical
density (OD) measurements were taken using a computerized microplate reader
(SPECTRAmax ® Plus384 , Molecular Devices Corporation, Sunnyvale, CA) with absorbance
measurements at 560 nm. Optical density readings were converted to percent of uninfected
control using an Excel spreadsheet by plotting CPE values versus log 10 of drug concentration .

Figure 1: Standard plate format for antiviral evaluation. Maximal drug concentration is placed in
the top well and a ten-fold dilution series is followed to the bottom well. The center four wells
are a killed control. Center bottom six wells are a viral control. Center top six wells are a cell
control.

2.14 Statistics

All confidence intervals were calculated using the confidence function in Microsoft Excel
for Mac (version 16.11. 1). Graphs and tables were also generated with Microsoft Excel for Mac
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(version 16.11.1) . P values where calculated using an unpaired student's t test from the Analysis
ToolPak of Microsoft Excel for Mac (version 16.11. 1). Variances were assumed unequal
, a more
conservative estimate than the assumption of equal variance. All P values were calculated
using
a two-tailed t test, which evaluates whether samples are different. If samples are found to
be
different, this test also confirms whether they are greater or lesser.

3 Results:
3.1 Initial 5 Passages of Influenza H3N2
Figure 2 shows the quantity of virus recovered from each subsequent mouse passage.
Mouse to mouse passaging within AG-129 mice resulted in increase of influenza A/Hong
Kong/4801/2014 H3N2 virus CCID50 over the first two to three passages, with mouse passage
1
(MPl) with a CCID50 of 104 ·28 (95% confidence interval: 103·5 - 105 ·0) increasing to the
viral
titer of MP3, with a CCID50 of 106 ·22 (95% confidence interval: 105 ·5 - 106 ·9). Following
this
viral concentration remained relatively constant through MPS (Figure 2).

3

MPl

MP2

MP3

MP4

MPS

Mouse Passage Number

·-------------------

Figure 2: The x axis represents the Log 10(Titer)/ml or the Log o(CCID50)/ml.
Mouse passage is
1
represented with MP#. MPl being mouse passage 1. All mouse passages were
aided by mannan
given concurrently with infection and intranasal rinses on day 1 and 2.
3.2 Evaluation of Disease Markers in MP4 Influenza H3N2
Intranasal inoculation with MP4 results both in weight loss, and in mortality
in AG-129
mice. The surviving mouse dropped to a minimum weight of 18 grams, a 29 .1
% weight loss
from its weight on the day of infection . A 33.8% weight loss from its maxima
l weight, which it
reached one day post infection.
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Figure 3: Evaluation of mortality and weight loss in AG-129 mice, inoculated intranasally with
MP4 and mannan. Mice were given intranasal rinses on day 1 and day 2.

3.3 Influenza H3N2 Passages Without Mannan and Rinses
All three groups showed a reduction in viral concentration from their original passages to
later passages (Figure 4 - 6). The two passages did not show a statistical difference between the
original mouse passage (MP3 or MPS) and the two non-original stock passages. Figure 4 shows
that mice inoculated with MP3, without intranasal rinses and mannan, had the greatest initial
reduction in viral concentration, with a CCIDS0 of 10239 (9S% confidence interval: 102 ·28 102·5). Figure five shows that mice inoculated with MPS under the same conditions of MP3
performed better, with a recovered homogenate with a CCIDS0 of 103·28 (9S% confidence
interval: 102 ·99 - 103 56). The highest CCIDS0 came from mice inoculated with MPS, with
mannan but no rinses (figure 6). This passage had a CCIDS0 of 104·8 (9S% confidence interval:
104.34_105.33).
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MP3 passage without mannan and rinses
7

E 6

~s
41
..,

I= 4
0

bi)3

.9 2
1
MP3 - Original

MP4 (no mannan,
no rinse)

MPS (no mannan,
no rinse)

Mouse PassageNumber

Figure 4: Mouse passage three (MP3), demarcated 'MP3 - Original ' was passaged twice in the
absence of mannan and intranasal rinses forming MP4 (no mannan, no rinse) and MPS (no
mannan, no rinse).

MPS passagewithout mannan and rinses
7

E 6
~5

41
..,

I= 4
0

bi)3

.9 2
1
MPS - Original

MP6 (no mannan,
no rinse)

MP7 (no mannan,
no rinse)

Mouse PassageNumber
Figure 5: Mouse passage three (MPS), demarcated 'MPS - Original' was passaged twice in the
absence of mannan and intranasal rinses forming MP6 (no mannan, no rinse) and MP7 (no
mannan, no rinse) .
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MPS passage without rinses
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Figure 6: Mouse passage three (MPS), demarcated 'MPS - Original' was passaged twice
in the
absence of intranasal rinses forming MP6 (no rinse) and MP7 (no rinse).

3.4 In Vitro Screening of Compounds Against Murine Norovirus

Of all compounds tested, only rupintrivir, carbodine, favipiravir and anisomycin
displayed antiviral activity. Figure 7 shows the selectivity index of these four antivirals ,
as well
as their cytotoxic concentration 50% (CC50) and their effective concentration 50% (EC50).

Compound

ccso

ECSO

SI

.Rupintrivir.........
....
...
....
..7.ug/ml.................1............ ......7
..ug/ml....... ..........
........
..........
.~.....
........
......
.........
.
·~·~
·~·~·~
·~·~····
·~·!
···. .......
>..320
....ug/m1.......................
....10..ug/m.1.....................
........
...........?...?.?.
....
...................
.Favipi.ravir
......
...........
.>.320.ug/ml...................
1oou.
......
g/ml ..........
.........
......
............
~ ..?..:.?..
~..............
.....
.
Anisomycin
9.5 ng/ml
3.1 ng/ml
3.1
Figure 7: The cytotoxic concentration 50% (CC50) is a measure of at what concentration
the
drug killed 50% of the cells. Effective concentration 50% (EC50) is a measure of at what
concentration the compound saved 50% of the cells. Selectivity index is the CC50 divided
by
EC50. It therefore represents how selective a compound is for the viral target versus the
host cell.
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4 Discussion:
4.1 Influenza H3N2 Morine Model:
Figure 2 showed an initial increase in viral CCID50 after serial passaging. The rise in
viral quantity from MPl to MP2, an increase in over a order of magnitude, suggests de novo
replication of influenza H3N2 in AG-129 mice. A result which is supported by figure 3,
which
shows mortality and weight loss resulting from infection with MP4. In addition, figure 3
also
shows that when aided with mannan and by day 1 and 2 intranasal rinses, the virus is capable
of
showing disease. Before this can be concluded definitively however, multiple steps must
be
taken. The virus would need to be plaque purified, and confirmed, by PCR or other methods
, to
be Influenza A Hong Kong/4801/2014 H3N2 virus. Furthermore, a larger study giving more
statistical certainty to the frequency of mortality and disease signs would need to be perform
ed.
Finally, a compound with known efficacy against influenza H3N2 would ideally be tested
in the
model. Confirming whether it is possible to protect against mortality by use of a therapeu
tic in
the model and showing whether there is crossover between the model and instances of human
infection.
Figures 4 and 5 shows that passaging ofH3N2 without mannan and intranasal rinses
results in a decrease concentration of virus. The reduction in MP3 to MP4 (no mannan, no
rinses), was greater than the reduction in MPS to MP6 (no mannan, no rinse) (p = .0109).
Showing MPS has developed either increased ability to survive or increased ability to replicate
relative to MP3. Figure 6 when compared with figure 5 shows that MPS had either increase
d
replication or survival when assisted by mannan than when not assisted by mannan (p =
.013).
De novo replication of MPS or MP3 without mannan and intranasal rinses is likely, as
neither mannan or intranasal rinses increase the rate of viral replication. If, however, the
virus is
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replicating deep within the lungs , intranasal rinsing may be necessary for the
virus to reach the
cells within which it undergoes replication . Further passaging will discern whethe
r virus levels
fall, remain constant or rise. Either a rise or constant level of virus suggest de
novo replication.
This is because each subsequent passage involves homogenization of virus in
1 ml of MEM and
then infection with 90 ul of this stock. In other words, the virus undergoes a
1: 11 dilution each
passage. This reduction may be more than a 1:11 dilution , as all virus injected
intranasally may
not reach the lungs. Considering this , consistently retrieving constant levels of
virus from one
passage to the next is a sign of de novo replication .

4.2 Antiviral Screening Against Murine Norovirus:
While rupintrivir displayed activity, its selectivity index is too low for therape
utic use.
Anisomycin also displays a small selectivity index. In addition to this , anisom
ycin has a low
CC50 at 9.5 ng/ml, meaning the compound displays high toxicity. The lack of
an upper bound on
the CC50 values of carbodine and favipiravir results because no toxicity was
seen at the
concentrations used on the plate. A definitive selectivity index for these compou
nds would
require an additional screen , which utilizes higher concentrations of the compou
nd then 320 µg
/ml.
Of the efficacious compounds , carbodine and favipiravir both show therapeutic
potential
(Figure 7). Carbodine with a selectivity index of at least 32, showed the greates
t potential.
Possible future steps include the evaluation of carbodine in the AG-129 lethal
model for murine
norovirus . While the compound has potential , carbodine is costly , at over 500
dollars for 5 mg.
Compounds with similar structures such as gentamycin , 5-azacytadine and 1-betaDArabinofuranisyl, could be tested against murine norovirus and may offer cheaper
alternatives.
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Finally, compounds found efficacious against murine norovirus could be screene
d in vitro
against human norovirus. This could provide an indication as to whether murine
norovirus
infection resembles human norovirus infection closely enough to act as a valid
model for
therapeutic evaluation.

5 Conclusion:
5.1 Influenza H3N2 Morine Model
Levels oflnfluenza A Hong Kong/4801/2014 H3N2 virus following mouse passage
one
showed an increase, suggesting adaption of virus and de novo replication (figure
2). Mouse
passage four was capable of mortality and weight loss (figure 3), when virus
was given
concurrently with mannan and intranasal rinses were performed day one and
two. This further
suggests de novo replication. It also indicates potential as a therapeutic model.
PCR verification
of viral strain has not yet been performed, so it is possible a contaminant has
caused the increase
in virulence. Passage of MP3 and MPS without mannan and intranasal rinses
resulted in a net
reduction of virus (Figures 4 - 6) after initial passaging. The subsequent passage
did not cause a
statistically significant change in the quantity of the virus.
If stable replication occurs without mannan and intranasal rinses in future passage
s, then

further projects may endeavor to adapt this future passage to replication within
BALB/c mice.
These mice provide a less expensive alternative to AG-129 mice and may prove
a better model
given that they possess normal interferon responses .
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5.2 Antiviral Screening Against Murine Norovirus
Of the compounds tested , rupintrivir , anisomycin, favipiravir , and carbodine showed
efficacy (figure 7). Of these efficacious compounds favipiravir and carbodine
possess the highest
selectivity indices, at >3.2 and >32 respectively. Favipiravir and carbodine selectiv
ity indices
lack an upper bound as they displayed no toxicity at the maximal concentration
tested (320
µg/ml).
Possible future directions include; evaluation of compounds in vitro in the human
norovirus model, identifying the upper bounds of the selectivity indices, in vivo
evaluation
against murine norovirus , and screening of compounds in the in vitro model of
human norovirus.
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Reflective Writing

During my years at Utah State University I dual majored in animal dairy and veterinary
science and biology as well as two minors, one in chemistry and one in computer science. In
addition to my academic work, I have worked three years for the Institute for Antiviral Research
here at Utah State University for the College of Agriculture and Applied Sciences. When building
a capstone experience, I wished to be able to expand both my academic knowledge of majors
and my knowledge of the field of virology .
My time here at USU provided me with an excellent understanding of in vivo antiviral
evaluation but I had done little work performing antiviral screens inside in vitro model systems.
In addition to a desire to explore different aspects of antiviral investigation, I also wanted the
opportunity to work independently, albeit supervised by a principle investigator, on a research
project of my own.
While these interests are in part meant to expound upon what I have enjoyed at Utah

.

State University, they are also intended to help me in my future pursuits. I intend to get a PhD
in Virology, which requires independent experience and expertise on my resume.
To achieve this, I reached out to Dr. E. Bart Tarbet, a principle investigator at the
Institute of Antiviral Research who works on a variety of projects in virology, including vaccine
evaluation, antiviral testing, and murine model development. We discussed my interests, and
the reasons for them, with Dr. Tarbet and we decided on three projects that I could work on for
my thesis. One project, was the adaption of influenza A subtype H3N2 into in murine model in
AG-129 mice (immune incompetent mice). These mice were chosen as previous attempts to
adapt the virus in immune competent mice, the BALB/c strain, had failed. In addition to the

adaption of influenza A virus, subtype H3N2, I also worked two other projects namely; the
adaption of human rhinovirus and respiratory syncytial virus to an AG-129 host. We were
unable to get either of these viruses to grow within mice, which supplied additional time in my
schedule for another project.
After conversing with Dr. Tarbet once again, it was decided that in addition to mouse
passaging for the adaption of influenza virus A subtype H3N2 I would also screen compounds in
vitro against murine norovirus. Murine norovirus is a model system which acts as an analog of
human noroviruses. This model is often necessitated by the difficulty of growing human
noroviruses both in vitro and in vivo in any animal but the natural human host.
Both these opportunities brought new experiences with them. Initially my time was split
between the laboratory and the scientific literature. When in the laboratory, I reached out to
other members of the institute for antiviral research, asking for their instruction on how to
perform techniques and assaysnew to me. This broadened my skillset, increasing my future
marketability within the field. When outside the laboratory, I looked over articles describing the
mechanism of action of various antiviral compounds as well as the life cycle of human and
murine noroviruses. There would be no use in finding an antiviral compound which had already
been discovered, so knowing which compounds had been found to have efficacy was valuable
information. In addition to this knowledge, by learning the mechanism of action of an antiviral
compounds, and relying on others researcher's descriptions of murine noroviruses lifecycle I
could predict which compounds might have efficacy in vitro.
This process proved itself invaluable to me as it allowed me to acclimatize myself to
research articles and other technically written documents. In addition, I was permitted to

develop hypotheses, develop a potential design for a study, reques
t authorization from Dr.
Tarbet, and then evaluate the hypothesis within the laboratory.
I repeated this process until I
had uncovered four potential antiviral compounds, which I will
be investigating further over this
summer.
In addition to the antiviral work, my studies on viral adaption for
murine model
development also required me to adjust my methods as I acquir
ed new information. Dr. Tarbet
and l's first hypothesis, namely that adaption within AG-129 mice
would allow sufficient respite
from immunity for the virus to begin replicating and evolving to
life in a murine host was not
correct. Initially passaging of all three viruses was unsuccessful.
This provided me with another
opportunity to peruse through scientific journals, this time in search
of techniques which can
aid in viral adaption within the host. Thanks to this search, and
to advice from discussions with
members of my laboratory, mannan and intranasal saline treatm
ents were both identified as a
potential aide for adaption. Mannan acted as a pathogen recogn
ition receptor inhibitor,
specifically by competing for the potential binding sites of the manna
n-binding lectins with
influenza A subtype H3N2, helping to spare them from contact
with these receptors. Intranasal
rinsing was utilized to wash the virus deeper into the lungs, and
expose it to new tissue and
cells for growth.
These adaption techniques were effective for influenza A subtyp
e H3N2. Having had
success with adaption and antiviral screening the next step for
my project was to make a
written product, my bachelor's thesis, and two products which
would aide in oral presentation
of the material a poster and a powerpoint presentation. This provid
ed an excellent opportunity
for me to become more familiar with statistics, a branch of mathe
matics often utilized in

for me to share my work, both
scientific fields. In addition to this it provided an opportunity
other students, when I presented my
with professors, during the defense of my thesis, and with
At this symposium, I was rewarded a
work at the biology undergraduate research symposium.
provided me with an opportunity to
prize for best presentation, showing that this project has
ning science clearly and
work at both the practice of science and on the art of explai
enthusiastically to others.
ne project for me because
In summation, this project embodied the ideal honors capsto
more time reading in scientific
it allowed me to: investigate more deeply into virology, spend
, perform independent esearch,
literature, explore the scientific methods, to test hypotheses
my local community.
and to explain my new understanding to individuals within

